We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

41 hedge funds and large institutions have $57.5M invested in Tempest Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

8% more funds holding

Funds holding: 38 → 41 (+3)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $90.7M → $57.5M (-$33.2M)

Holders
41
Holders Change
+3
Holders Change %
+7.89%
% of All Funds
0.9%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
5
Increased
13
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
+$1.17M
2
Northern Trust
Northern Trust
Illinois
+$586K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$563K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$321K
5
State Street
State Street
Massachusetts
+$237K

Top Sellers

Rank Fund Capital Flow
1
AIC
AWM Investment Company
New York
-$897K
2
ASP
Adams Street Partners
Illinois
-$341K
3
PM
Prosight Management
Texas
-$181K
4
Deutsche Bank
Deutsche Bank
Germany
-$123K
5
Renaissance Technologies
Renaissance Technologies
New York
-$63K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$12.6M – – –
FM
2
Frazier Management
Washington
$9.93M – – –
GPP
3
Great Point Partners
Connecticut
$9.16M – – –
B
4
Bpifrance
France
$7.67M – – –
BlackRock
5
BlackRock
New York
$3.44M +$129K +80 +3%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.84M +$563K +349 +21%
ASP
7
Adams Street Partners
Illinois
$2.62M -$341K -211 -10%
Renaissance Technologies
8
Renaissance Technologies
New York
$1.43M -$63K -39 -4%
SB
9
Samsara BioCapital
California
$1.33M +$1.17M +726 +314%
IBT
10
International Biotechnology Trust
United Kingdom
$1.26M – – –
State Street
11
State Street
Massachusetts
$1.03M +$237K +147 +25%
Northern Trust
12
Northern Trust
Illinois
$797K +$586K +363 +171%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$538K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$438K +$14.5K +9 +3%
GC
15
GMT Capital
Georgia
$380K – – –
PM
16
Prosight Management
Texas
$370K -$181K -112 -30%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$276K +$321K +199 New
Wells Fargo
18
Wells Fargo
California
$264K +$189K +117 +158%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$204K +$37.1K +23 +19%
Charles Schwab
20
Charles Schwab
California
$139K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$137K +$11.3K +7 +8%
Squarepoint
22
Squarepoint
New York
$130K +$66.2K +41 +77%
N
23
Nuveen
North Carolina
$106K – – –
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$103K – – –
New York State Common Retirement Fund
25
New York State Common Retirement Fund
New York
$68K – – –
1
2

TPST Hedge Fund Activity: Q3 2019 in Review

41 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2019, worth a combined $57.5M — down 37% from $90.7M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TPST positions and 2 closed out — a net gain of 3 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Samsara BioCapital, adding an estimated $1.17M. The largest seller was AWM Investment Company, exiting entirely with an estimated $897K sold.

  • 41 institutional investors held Tempest Therapeutics (TPST) as of Q3 2019, up from 38 in Q2 2019.
  • Funds reported $57.5M of Tempest Therapeutics stock for Q3 2019, down 37% quarter-over-quarter.
  • 5 funds opened new Tempest Therapeutics positions in Q3 2019 and 2 closed out, a net change of +3 holders.
  • The largest Tempest Therapeutics buyer in Q3 2019 was Samsara BioCapital, an estimated $1.17M added.
  • The largest Tempest Therapeutics seller in Q3 2019 was AWM Investment Company, an estimated $897K sold.

Based on aggregated 13F filings for Q3 2019.